A robust immunohistochemical assay for detecting PTEN expression in human tumors.
about
Where now for anti-EGF receptor therapies in colorectal cancer?Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducibleCan we accurately report PTEN status in advanced colorectal cancer?Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.A new hypothesis for the cancer mechanism.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate CancerEvaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionNovel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsA Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Functions and Regulation of the PTEN Gene in Colorectal Cancer.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsAnalytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusionPTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
P2860
Q31038305-66DCA65E-2614-4952-9B70-610837A1B95EQ34455301-78D2FD50-115A-4150-A127-6E287926E781Q34574472-D606FEB6-CDFE-4840-AD2A-4DA9C6AD4EBEQ35101357-43D5DAD4-B837-4869-9202-2CE9FC9BE504Q35374477-422AD8F0-BDB8-4AE5-8991-AB1D25C8F12FQ35540013-BC428D17-4F00-4B34-BF6A-642CF208826AQ35545322-9E910228-15F8-4800-ADC0-4058BDA91E9CQ35954093-54D945EB-3CC2-4D7D-B06E-311258282948Q36199762-B8BA36D1-9D10-419C-A6C5-D92DC1EAF5F5Q36464689-634AF133-B0AB-43C1-8B25-738F8E4FB581Q36724548-E8D4157C-829B-4DF9-B179-7338F8ED75C1Q36727409-BB36ABE6-8B12-4573-ACED-F6C734D0BADBQ36901964-DAC2E929-F368-4DFE-A028-430572F6C1D8Q36959119-29B6C95A-B2CE-45CE-B623-F770A80E6750Q37049376-30B59ADF-8F56-4766-8227-6010C9E57DD1Q37065849-D2578FBC-F48F-43A6-AC56-35A6313ADB35Q37080378-2D988FB7-8516-4FC5-9CBF-5E3B05C24A04Q37221249-B8525397-83E9-4317-94B1-2498A52CB974Q37236257-B4F3648D-FF64-4D8E-9E32-8DCCFAE055EEQ37536970-33CDBC98-691B-4228-AF2C-6BD9DFC73A4EQ37690039-2028B250-17D2-4EA2-B2A8-AFB2DFBBF693Q37737860-22DE96FB-1C1A-43FA-B1D0-884E2A5E6726Q37856722-8A96C902-E57A-438A-8E91-98D92FDC79C1Q38182985-4888825D-4F97-422F-90F2-8D01C3DEBF1FQ38326102-46890B61-DD60-4331-A3E4-FFE10F60C003Q38738670-0AA96135-8410-4F84-95AB-3F478AAFD09EQ38833458-CE8F5F95-7B66-4733-8B5D-B15D669B6309Q42119481-4BC7DD97-6897-4AAC-AA6D-1529CB1C37AAQ42371556-C69A5B41-A23D-469A-BEBB-E3185326F467Q43805357-61BC8E98-228F-4637-9E56-0CD99862293AQ44610950-EDDF5EDC-C944-40BA-87C4-1AD55357DE77Q45030051-FC1C991B-981A-4D78-A00A-48C1A5358644Q45251986-D9568E9E-5387-463F-811B-61069B43C4BEQ49081390-58FCF1F9-CC05-4BD8-B542-C3D5DF61A4AB
P2860
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@en
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@nl
type
label
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@en
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@nl
prefLabel
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@en
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@nl
P2093
P1476
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
@en
P2093
Amy Carlson
Cynthia Prass
Eliso Tikishvili
Jerry Lanchbury
Jorja Degrado
Steven Stone
Zaina Sangale
P304
P356
10.1097/PAI.0B013E3181F1DA13
P577
2011-03-01T00:00:00Z